359028-91-4

Upstream product

• 2740-83-2 3-(TRIFLUOROMETHYL)BENZYLAMINE 
• 359028-90-3 (6S,8R)-1,3-Dichloro-4-oxo-8-(3-phenyl-propyl)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid ethyl ester 
• 359028-87-8 (2S,4R)-5-Cyano-4-(3-phenyl-propyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 359028-86-7 (2S,4R)-5-Methoxy-4-(3-phenyl-propyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 359028-88-9 (2S,4R)-5-Cyano-4-(3-phenyl-propyl)-pyrrolidine-2-carboxylic acid ethyl ester 
• 284024-88-0 ethyl (2S,4R)-N-Boc-4-(3-phenylpropyl)pyroglutamate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 

Downstream Products

• 359028-92-5 (6S,8R)-1-Chloro-4-oxo-8-(3-phenyl-propyl)-3-(3-trifluoromethyl-benzylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid 

Relevant academic research and scientific papers

Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease

Starting from a hexapeptide boronic acid lead, 3-amino bicyclic pyrazinones as novel β-sheet dipeptide mimetics have been designed and synthesized. Side-chain manipulation of this scaffold generated a series of potent, nonpeptidic inhibitors of HCV NS3 protease.